Emerging retatrutide, a dual -action medication targeting simultaneously GLP-1 and GIP receptors, is generating considerable buzz within the healthcare community. Preliminary clinical studies have revealed significant reductions in physical weight and advancements in metabolic markers for patients with excess weight . Researchers believe this groun